Key Points
- Agios Pharmaceuticals insider Sarah Gheuens sold 7,866 shares for approximately $296,470 under a pre-arranged Rule 10b5-1 trading plan, reducing her holdings by 12.58% to 54,645 shares.
- AGIO opened at $38.12, with a market capitalization of about $2.28 billion, and trades between a 52-week range of $22.24 to $46.00. The company reported quarterly revenue of $44.75 million but posted an EPS loss of $1.69, missing estimates.
- Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $41.50; institutional investors also increased several positions, including a significant purchase by Assenagon Asset Management.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Sarah Gheuens sold 7,866 shares of the stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $37.69, for a total transaction of $296,469.54. Following the transaction, the insider owned 54,645 shares in the company, valued at approximately $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Sarah Gheuens also recently made the following trade(s):
- On Thursday, October 22nd, Sarah Gheuens sold 500 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.52, for a total transaction of $18,760.00.
- On Wednesday, October 21st, Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $37.53, for a total transaction of $55,882.17.
- On Tuesday, August 4th, Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00.
Agios Pharmaceuticals Stock Performance
Shares of AGIO opened at $38.12 on Thursday. The company has a 50 day moving average price of $33.64 and a 200-day moving average price of $31.65. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock has a market capitalization of $2.28 billion, a PE ratio of -5.44 and a beta of 0.63.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.65) by ($0.04). The business had revenue of $44.75 million for the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.83 EPS for the current year.
Institutional Trading of Agios Pharmaceuticals
Institutional investors have recently modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of Agios Pharmaceuticals by 4.0% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company's stock worth $960,000 after buying an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,893 shares of the biopharmaceutical company's stock worth $363,000 after acquiring an additional 1,428 shares in the last quarter. Inspire Investing LLC raised its stake in shares of Agios Pharmaceuticals by 4.7% during the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company's stock worth $636,000 after acquiring an additional 861 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Agios Pharmaceuticals by 1,714.6% during the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company's stock valued at $62,723,000 after acquiring an additional 1,782,457 shares during the last quarter. Finally, Tidal Investments LLC lifted its position in Agios Pharmaceuticals by 12.0% during the second quarter. Tidal Investments LLC now owns 16,100 shares of the biopharmaceutical company's stock valued at $597,000 after acquiring an additional 1,724 shares during the last quarter.
Wall Street Analyst Weigh In
AGIO has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Truist Financial dropped their target price on Agios Pharmaceuticals from $39.00 to $37.00 and set a "buy" rating on the stock in a research report on Wednesday, October 7th. Citigroup lifted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a "buy" rating in a report on Friday, July 31st. HC Wainwright boosted their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Finally, TD Cowen upgraded Agios Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $41.50.
Read Our Latest Stock Analysis on AGIO
Agios Pharmaceuticals Company Profile
(
Get Free Report)
Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.
Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
